SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg10/5/2006 3:43:01 AM
   of 2240
 
Medarex Amends Indenture Governing 2.25% Convertible Senior Notes due 2011 and Announces Close of Consent Solicitation
Wednesday October 4, 7:30 pm ET

PRINCETON, N.J., Oct. 4 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today that it has received the requisite consent to adopt the proposed amendments to the indenture (the "Indenture") governing its outstanding 2.25% Convertible Senior Notes in the aggregate principal amount of $150 million due May 15, 2011 (the "Notes"), pursuant to its previously announced consent solicitation from the holders of record of the Notes on September 21, 2006, described in the Consent Solicitation Statement, dated September 22, 2006 (the "Consent Solicitation Statement"), as supplemented by the supplement to the Consent Solicitation Statement, dated October 2, 2006 (the "Supplement" and together with the Consent Solicitation Statement, the "Supplemented Consent Solicitation Statement"). Adoption of the proposed amendments required the consent of holders of at least a majority of the aggregate principal amount of the outstanding Notes under the indenture.

Medarex and the trustee of the Notes have entered into a supplemental indenture (the "First Supplemental Indenture") effecting the amendments to the Indenture and consents with respect to the Notes may no longer be revoked. As consideration for the amendments to the Indenture and waiver of related defaults and events of defaults, as set forth in the First Supplemental Indenture, Medarex will no longer have the right to redeem the Notes prior to May 15, 2010. At any time on or after May 15, 2010 and until May 14, 2011, Medarex will have the right to redeem the Notes in cash, in whole or in part, but only if the closing sale price of its common stock for at least 20 of the 30 consecutive trading days immediately prior to the day Medarex gives notice of redemption is greater than 150% of the applicable conversion price on the date of the notice. The cash redemption price for the period from May 15, 2010 to May 14, 2011 will equal 100.3% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest, if any, to, but not including, the date of redemption.

This announcement is not an offer to purchase or sell, a solicitation of an offer to purchase or sell or a solicitation of consents with respect to any securities. The Consent Solicitation was made solely pursuant to the Supplemented Consent Solicitation Statement.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext